Hepion: Rises on FDA clearance for COVID-19 drug candidate study

Hepion Pharmaceuticals

22/12/2020 14:31

** Drug developer's  HEPA.O  shares up 3.54% to $2.20
    ** Co says U.S. FDA has accepted its investigational new
drug application for co's lead candidate, CRV431, for the
treatment of COVID-19 (https://bit.ly/2WEVJGa)
    ** Says CRV431 poised to move directly into Phase 2 clinical
study for COVID-19 
    ** Adds new drug application expands potential indications
for CRV431 beyond non-alcoholic liver disease (NASH)
    ** CRV431 is currently in clinical development for NASH, and
has demonstrated antiviral activities against hepatitis viruses
in preclinical studies - HEPA
    ** HEPA down ~60% this year, as of last close

 



 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))